CO41 Comparative Effectiveness of Glucagon-like Peptide 1 Agonists Vs Dipeptidyl Peptidase 4 Inhibitors on Liver Outcomes in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Fatty Liver Disease
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.130
https://www.valueinhealthjournal.com/article/S1098-3015(24)00245-6/fulltext
Title :
CO41 Comparative Effectiveness of Glucagon-like Peptide 1 Agonists Vs Dipeptidyl Peptidase 4 Inhibitors on Liver Outcomes in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Fatty Liver Disease
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00245-6&doi=10.1016/j.jval.2024.03.130
First page :
Section Title :
Open access? :
No
Section Order :
10721